Better Risk Stratification May Refine Early Myeloma Treatment - AJMC
Better Risk Stratification May Refine Early Myeloma Treatment AJMC
Multiple Myeloma News
Managing Multiple Myeloma Relapse Anxiety: Tips and Support - Everyday Health
Managing Multiple Myeloma Relapse Anxiety: Tips and Support Everyday Health
Reversing T Cell Exhaustion Improves Effectiveness of Myeloma Immunotherapies - Mount Sinai
Reversing T Cell Exhaustion Improves Effectiveness of Myeloma Immunotherapies Mount Sinai
Moving Bispecifics and Prophylaxis to Outpatient Multiple Myeloma Care - CancerNetwork
Moving Bispecifics and Prophylaxis to Outpatient Multiple Myeloma Care CancerNetwork
Giants of Cancer Care: OncLive Honors 14 Pioneers - OncLive
Giants of Cancer Care: OncLive Honors 14 Pioneers OncLive
Myeloma Paper of the Day, May 18th Suggested by Robert Orlowski - Oncodaily
Myeloma Paper of the Day, May 18th Suggested by Robert Orlowski Oncodaily
Sticking with my myeloma treatment all came down to a smartphone app - Rare Cancer News
Sticking with my myeloma treatment all came down to a smartphone app Rare Cancer News
Improving how multiple myeloma is understood and treated - Mayo Clinic News Network
Improving how multiple myeloma is understood and treated Mayo Clinic News Network
Monoclonal Gammopathy as a Potential Cause of Pure Red Cell Aplasia: A Case Report and Literature Review - Cureus
Monoclonal Gammopathy as a Potential Cause of Pure Red Cell Aplasia: A Case Report and Literature Review Cureus
Using Novel Mechanisms of Action as Myeloma CAR T Bridging Therapy - Targeted Oncology
Using Novel Mechanisms of Action as Myeloma CAR T Bridging Therapy Targeted Oncology
Multiple Myeloma: Improved Prognosis With the Latest Treatments - Memorial Sloan Kettering Cancer Center
Multiple Myeloma: Improved Prognosis With the Latest Treatments Memorial Sloan Kettering Cancer Center
Hope, Healing, and Gratitude: A Life Reimagined After Multiple Myeloma | News - Yale Medicine
Hope, Healing, and Gratitude: A Life Reimagined After Multiple Myeloma | News Yale Medicine
Multiple myeloma cells adapt after immunotherapy, helping explain why many patients relapse - Medical Xpress
Multiple myeloma cells adapt after immunotherapy, helping explain why many patients relapse Medical Xpress
Are multiple myeloma rates higher in Western New York? - Roswell Park Comprehensive Cancer Center
Are multiple myeloma rates higher in Western New York? Roswell Park Comprehensive Cancer Center
“Massive Shift” Prompts ASCO to Update Guideline for Multiple Myeloma - Oncology News Central
“Massive Shift” Prompts ASCO to Update Guideline for Multiple Myeloma Oncology News Central
Multiple Myeloma: Understanding the Unseen Burdens Beyond Disease - Sanofi
Multiple Myeloma: Understanding the Unseen Burdens Beyond Disease Sanofi
How Might CAR T Cells and Bispecifics Evolve in Multiple Myeloma Therapy? - CancerNetwork
How Might CAR T Cells and Bispecifics Evolve in Multiple Myeloma Therapy? CancerNetwork
Five Under 5: Top Oncology Videos for the Week of 5/10 - OncLive
Five Under 5: Top Oncology Videos for the Week of 5/10 OncLive
Rohit Gosain: Four Bispecific Antibodies for Multiple Myeloma Treatment - Oncodaily
Rohit Gosain: Four Bispecific Antibodies for Multiple Myeloma Treatment Oncodaily
Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma - OncLive
Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma OncLive
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial - Nature
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial Nature
When Should Oncologists Treat Smoldering Multiple Myeloma? - ASCO Daily News
When Should Oncologists Treat Smoldering Multiple Myeloma? ASCO Daily News
Multiple Myeloma: Diagnosis and Treatment - American Academy of Family Physicians | AAFP
Multiple Myeloma: Diagnosis and Treatment American Academy of Family Physicians | AAFP
MRD in Multiple Myeloma From Foundations to Future Directions – SPCC - Oncodaily
MRD in Multiple Myeloma From Foundations to Future Directions – SPCC Oncodaily
Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort - Nature
Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort Nature
FDA Grants Fast Track Designation to OPN-6602 for Multiple Myeloma - Targeted Oncology
FDA Grants Fast Track Designation to OPN-6602 for Multiple Myeloma Targeted Oncology
Antibody Therapy Eradicates Traces of Multiple Myeloma in Preliminary Trial - University of Miami
Antibody Therapy Eradicates Traces of Multiple Myeloma in Preliminary Trial University of Miami
Is a Functional Cure for Multiple Myeloma Within Reach? - CUREtoday.com
Is a Functional Cure for Multiple Myeloma Within Reach? CUREtoday.com
Multiple myeloma mortality rates decline with advances in targeted therapies - news-medical.net
Multiple myeloma mortality rates decline with advances in targeted therapies news-medical.net
Peripheral blood cfDNA detection using clonoSEQ assay in multiple myeloma is concordant with bone marrow and clinical biomarkers - Nature
Peripheral blood cfDNA detection using clonoSEQ assay in multiple myeloma is concordant with bone marrow and clinical biomarkers Nature
Inflammatory immune cells predict survival, relapse in multiple myeloma - WashU Medicine
Inflammatory immune cells predict survival, relapse in multiple myeloma WashU Medicine
Diets for MGUS, Smoldering Myeloma, and Multiple Myeloma: Q&A With MSK Cancer and Nutrition Experts - Memorial Sloan Kettering Cancer Center
Diets for MGUS, Smoldering Myeloma, and Multiple Myeloma: Q&A With MSK Cancer and Nutrition Experts Memorial Sloan Kettering Cancer Center
Innovations extending survival in multiple myeloma therapy - Penn Medicine
Innovations extending survival in multiple myeloma therapy Penn Medicine
Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma - The University of Alabama at Birmingham
Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma The University of Alabama at Birmingham
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium | Blood Cancer Journal - Nature
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium | Blood Cancer Journal Nature
Minimal Residual Disease Testing in Multiple Myeloma - ASCO Daily News
Minimal Residual Disease Testing in Multiple Myeloma ASCO Daily News
EHA 2026 preview – a Monumental boost to J&J’s Talvey hopes | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
EHA 2026 preview – a Monumental boost to J&J’s Talvey hopes | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Study Identifies Why Multiple Myeloma May Return After Immunotherapy - CUREtoday.com
Study Identifies Why Multiple Myeloma May Return After Immunotherapy CUREtoday.com
Enhanced dynamic risk stratification of smoldering multiple myeloma - Nature
Enhanced dynamic risk stratification of smoldering multiple myeloma Nature
Role of Dual Maintenance Remains Uncertain in Multiple Myeloma - Targeted Oncology
Role of Dual Maintenance Remains Uncertain in Multiple Myeloma Targeted Oncology